These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29717552)

  • 41. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
    Elborn JS; Ramsey B; Wainwright C; Boyle M
    Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
    [No Abstract]   [Full Text] [Related]  

  • 42. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

  • 43. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation.
    Pohl K; Nichols DP; Taylor-Cousar JL; Saavedra MT; Strand MJ; Nick JA; Bratcher PE
    PLoS One; 2018; 13(12):e0209026. PubMed ID: 30540818
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.
    Sharma D; Xing S; Hung YT; Caskey RN; Dowell ML; Touchette DR
    Orphanet J Rare Dis; 2018 Sep; 13(1):172. PubMed ID: 30268148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
    Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
    Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis.
    Jarosz-Griffiths HH; Scambler T; Wong CH; Lara-Reyna S; Holbrook J; Martinon F; Savic S; Whitaker P; Etherington C; Spoletini G; Clifton I; Mehta A; McDermott MF; Peckham D
    Elife; 2020 Mar; 9():. PubMed ID: 32118580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
    Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
    [No Abstract]   [Full Text] [Related]  

  • 48. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
    Mayer M
    Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
    [No Abstract]   [Full Text] [Related]  

  • 49. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4
    Roehmel JF; Ogese MO; Rohrbach A; Mall MA; Naisbitt DJ
    J Allergy Clin Immunol; 2021 Feb; 147(2):753-756. PubMed ID: 32526307
    [No Abstract]   [Full Text] [Related]  

  • 51. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: a prospective multicenter cohort study in Sweden.
    Al Shakirchi M; Sorjonen K; Hjelte L; Klingspor L; Bergman P; Ericson P; Svedberg M; Lindberg U; Hansen C; Monestrol I
    Ther Adv Respir Dis; 2024; 18():17534666241254090. PubMed ID: 38780228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden.
    Lindblad A; Monestrol I; Gilljam M; Krantz C; McGarry LJ; Banefelt J; Aldvén M
    J Med Econ; 2024; 27(1):897-906. PubMed ID: 38939921
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR.
    Drummond D; Dana J; Berteloot L; Schneider-Futschik EK; Chedevergne F; Bailly-Botuha C; Nguyen-Khoa T; Cornet M; Le Bourgeois M; Debray D; Girard M; Sermet-Gaudelus I
    J Cyst Fibros; 2022 Mar; 21(2):212-219. PubMed ID: 34454846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability.
    Vonk SEM; van der Meer-Vos M; Bos LDJ; Neerincx AH; Majoor CJ; Maitland-van der Zee AH; Mathôt RAA; Kemper EM;
    Ther Drug Monit; 2021 Aug; 43(4):555-563. PubMed ID: 33165217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis.
    Reix P; Tatopoulos A; Ioan I; Le Bourgeois M; Bui S; Choukroun ML; Bessaci-Kabouya K; Gerardin M; Bokov P; Da Silva J; Paillasseur JL; Burgel PR;
    J Cyst Fibros; 2022 Jan; 21(1):155-159. PubMed ID: 34183285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.